BrainBeams Health

BrainBeams Health operates at the intersection of neurotechnology, digital health, wearables and workplace wellness. Its stated positioning is differentiated from conventional productivity software and stimulant-based focus products by using a drug-free wearable intended to modulate brain activity and provide support when concentration is needed. The company also emphasizes a simple application and fast effect, which suggests a consumer-facing experience rather than a complex clinical workflow. Its product descriptions reference both workplace users and adults with ADHD, giving it potential relevance across occupational wellness, personal health and mental-wellness segments. However, the available profile does not identify validated clinical outcomes, regulatory clearances, commercial customers or distinct named competitors. It is therefore not possible to place BrainBeams precisely against companies such as established neurostimulation or wearable brands without risking unsupported comparisons. With two grants totaling $202,081 and an employee range of one to ten, BrainBeams currently appears to be an early-stage specialist rather than a scaled category leader.

BrainBeams Health was founded in 2023 and has followed an early research-and-development trajectory supported by grant financing. The first recorded grant, $64,598, was announced on Dec 6, 2023. A second and larger grant of $137,483 followed on Dec 6, 2024, bringing cumulative funding to $202,081 and making the later award a clear financing inflection point. The company’s described product scope includes the BrainBeams Wearable Device and the FocusBoost App, indicating an ambition to pair hardware-based neuromodulation with a software layer for concentration support. Its current employee band of one to ten suggests a small development team, while no hiring expansion, layoffs or workforce milestones are documented. There are also no recorded commercial launches, partnerships or additional financing events after December 2024 in the available profile. The trajectory therefore shows continued funded product development, but not yet evidence of scaled distribution, substantial headcount growth or proven market adoption.